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1. OBJ ECTlVE 
The primary objective of the D.O.E. program at The University of Tennessee 
Medical Center is the development of in vivo methods for the detection and evaluation 
of tumors in humans. During this three-year period, we focused on utilizing positron 
emission tomography (PET) to monitor the distribution and pharmacokinetics of a 
current BNCT agent, p-boronophenylalanine (BPA) by labeling it with a fluorine-I 8, a 
positron emitting isotope. The PET data was then used to develop enhanced treatment 
planning protocols. The study also involved the synthesis of new tumor selective 
BNCT agents that could be labeled with radioactive nuclides for the in vivo detection of 
boron. 
During the initial phase of this study we synthesized the fructose complex of a 
fluorinated analogue of BPA and carried out PET biodistribution studies in glioblastoma 
multiforme patients who were then treated by BNCT at either Brookhaven National 
Laboratory or at The Massachusetts Institute of Technology in collaboration with 
Harvard Medical School. We were able to utilize the in vivo biodistribution data of 
para-boronophenylalanine labeled with fluorine-I 8 to develop enhanced PET based 
dosimetry calculations that more accurately matched clinical outcomes. During the 
next phase of the program we propose investigate the use of fluorine-I8 labeled PET 
as a general tumor imaging agent and to train students in the scientific aspects of 
nuclear medicine. 
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II. RESEARCH ACCOMPLISHMENTS 
I am pleased to report that this has been a productive period for the D.O.E. 
BNCT Program at The University of Tennessee. Twenty-five articles and book 
chapters have resulted from this research. Thirty-nine referred research abstracts of 
presentations have also been published. I was invited to present lectures at nineteen 
universities and scientific meetings. In addition, six postdoctoral students as well as 
twenty graduate and undergraduate students received training. 
A. Dosimetry Calculations 
The fructose complex of fluorine-I 8 labeled p-boronophenylalanine, "F-BPA-F 
(I), an analogue of the agent currently being used in BNCT was first prepared in our 
laboratories, used to image brain tumor patients, and utilized to generate new BNCT 
1 
treatment plans. A representative PET scan of a glioblastoma multiforme (GBM) 
patient is shown in Figure 1. It reveals an area of intense uptake in the right posterior 
parietal region that corresponds to the location of the lesion as seen on CT and MRI, 
Figure 1 (next page). 
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Figure 1. Pre-operative PET Scan and uptake curves of a 
Glioblastoma Patient. The time activity curve 
demonstrates selective uptake in the tumor as 
compared to normal brain tissue. At 52 minutes post 
injection, the ratio of tumor:brain activity was 
approximately 3.1. 
The patient underwent two additional PET studies using I8F-BPA-F. The first 
was carried out six weeks post craniotomy and showed residual focal uptake in the 
medial portion of the original tumor, corresponding to a site of known remaining tumor 
as confirmed by the neurosurgeon. 
Traditional treatment planning for BNCT is carried out using computed 
tomography (CT) or magnetic resonance imaging (MRI) to delineate the tumor from the 
su rro u nd in g ti ssu es . 1i213i415 In the case of GBM, the scalp, skull, normal brain, tumor, 
and 2 cm target regions around the tumor (1-3 cm) are typically demarcated for 
treatment planning. White matter, dark matter, and cerebral structures are not typically 
demarcated for treatment planning purposes. GBM cannot be demarcated even 
though CT and MRI images appear to possess distinct tumor boundaries since the 
tumor is infiltrative in nature. To address this problem, whenever possible in the trials 
at Brookhaven National Laboratory, a patient with a GBM was given an intravenous 
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loading dose of BPA prior to neurosurgical debulking. Some of the pathological 
specimens obtained by the neurosurgeon were analyzed to determine the boron 
concentrations. This technique does provide accurate, but limited, boron 
concentrations for the tumor and, in some cases, a few areas immediately bordering 
the tumor. The boron distribution data so obtained is averaged to provide a constant 
value for the dose calculations, Le. a homogeneous boron distribution in the tumor is 
assumed. Aside from PET data obtained using 18F-BPA described earlier, there exists 
little information about the boron distribution in post surgical and post BNCT GBM 
patients. 
Positron emission tomograms can be obtained that qualitatively and 
quantitatively represent the boron distribution in vivo by fluorinating BPA with fluorine- 
18.6ii7i8i9 Since 18F-BPA is not metabolized in vivo, PET tomograms should reflect the 
actual boron distribution in a given patient." We utilized PET scans to provide three 
dimensional boron distribution maps, that were then used for macroscopic dose 
calculations in conventional neutron transport codes such as the SERA code 
developed at the Idaho National Engineering and Environmental Laboratory (INEEL). 
SERA is a modification of traditional Monte-Carlo based neutron transport codes 
that calculate the dose from the (n,a), (n,ay), and (n,p) reactions and has modifications 
that make it especially suited for BNCT.l' Because the majority of the micro-dose 
(-65%) derives from the "B(r~,a)~Li reaction, the distribution of boron determines the 
major variability in the  macro-dose. 
In this study, "F-BPA-fructose was prepared and then administered to each 
patient who received -370 mBq (IO mCi) of the "F-BPA-fructose. PET scans were 
acquired on an ECAT EXACT 921 whole-body PET system (SiemenslCTI, Knoxville, 
TN) that produces 47 image slices over a 16.2 cm axial field of view. Dynamic 
emission images were acquired using twelve 10 sec frames, five 60 sec frames, and 
six 5 min frames, followed by 10 min frames up to 2 hr post injection. The actual time 
in the PET scanner was determined by the patient's ability to tolerate lying on the 
gantry. All images were reconstructed using measured attenuation correction with 
filtered backprojection, a zoom factor of 2, and a 0.35 pixel -' Hann filter. In order to 
avoid problems due to patient orientation in the scanner, treatment plans were 
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performed using only the PET images. The boron distribution then was used to linearly 
scale the treatment plan as described below. This technique eliminated co-registration 
problems that arise when MRI and PET images are both used in planning. 
The dose calculations were obtained using the code, SERA, developed at the 
Idaho National Engineering and Environmental Laboratory (INEEL) in conjunction with 
Montana State University.”* The definition of structures was accomplished with SERA 
using PET images. The code generates neutron tracts and interactions in a user 
defined nuclear species environment. SERA was used to process the PET images by 
delineating the tumor and various other cerebral structures in parallel planes which 
resulted in a three-dimensional map of the scalp, skull, normal brain, and tumor. The 
neutron transport calculations were then run for the nuclear species commonly found in 
the body at normal concentrations with ’OB being defined everywhere as 1 .O ppm. The 
isodose contours initially generated reflect the dose due to the neutrons reacting with 
normal body composition of nuclear species and a constant homogeneous ’OB 
distribution. Boron information was used as a post-processing linear scale factor for the 
isodose contours generated by SERA. In the case of current treatment planning, the 
’OB was input as a constant homogeneous value for the normal brain with the tumor 
being a three dimensional step function that is 3.5-4.5 times that of the normal brain. In 
this study, a ratio of 3.51 was used in these calculations, as is usually done clinically, 
that corresponds to 45.5 ppm and 13 ppm tumor to normal tissue respectively. Since 
the maximal ‘OB measured in a GBM to date has been found to be no larger than -50 
ppm, a linear post-processing method has been shown to be adequate to calculate 
correct doses. SERA was run with the geometries determined by PET scans to select 
the optimal beam direction to obtain the maximum neutron fluence to the tumor and the 
surrounding edema. The isodose contours produced by SERA were then scaled by a 
three dimensional step function at the site of the tumor with the boron concentration 4.5 
times that of the surrounding tissue to produce conventional treatment plans (though 
based on PET scans). The output of SERA was then scaled with the PET data 
containing all boron concentrations (which incorporates the inhomogenieties) to 
construct the new isodose contours. Both sets of isodose curves were compared both 
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analytically and visually. The planes chosen were determined visually to be the planes 
with largest tumor area (i.e. approximately the centroid of the tumor). 
The data from six patients with glioblastoma multiforme were analyzed. The 
dynamic scans were plotted and compared with the simultaneously measured activity 
from venous sampling. In all cases, the boron levels in blood and normal brain tissue 
(Le. greater than 3 cm from the center of the tumor) levels peaked within 1-3 min and 
fell off in approximately 8 min in an exponential decline. The tumor (measured at the 
center) boron levels rose quickly in the first 5 min and then fell off gradually from rather 
flat peak at approximately 40 min. The time activity curves obtained for a two hour 
period indicate that the optimal time to treat is -40-60 min after the initial infusion 
(which is approximately the time frame used in the clinical trials). 
Treatment plans were generated using the 18F-BPA-PET scan images and 
SERA. The output from SERA represents the statistical solution of the Boltzmann 
transport equation for neutrons in the normal brain with a homogeneous distribution of 
-13 ppm boron. The resulting isodose contours were qualitatively similar to those 
obtained using computed tomography (CT) or magnetic resonance (MR) images to 
generate the isodose contours. The isodose contours were then scaled with the 
standard assumption of the boron concentration being a homogeneous three 
dimensional step function. The boron to normal brain tissue ratio was taken to be 4:l 
as in the standard model. A second set of isodose contours was then generated by 
taking the SERA output and scaling it by the boron concentrations determined by the 
I8F-BPA-PET PET images. Representative examples for two patients are presented 
in Figure 2. 
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Figure 2: Two patients with PET scaled isodose curves 
(on the left) and standard curves on the right. 
Although the planes chosen shown are visually ones with largest tumor area, the 
results were found to be similar in other planes. Qualitatively, the isodose contours 
based upon the PET data are smaller and less regular than are those seen using the 
conventional calculations. The two methods of calculating the dose reveal differences 
that are easily identified by examining the percent difference columns that is calculated 
by dividing the isodose area calculated by the 18F-BPA boron concentrations by the 
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area generated using conventional methods with the resulting quotient being multiplied 
by one hundred. 
Figure 3 (next page) contains serial MRI images of a patient immediately after 
surgery (3A), -2 weeks after surgery (3B), -1 month after BNCT (3C), and -6 weeks 
after BNCT. The corresponding PET generated treatment plan indicated that the tumor 
would be destroyed but that the edematous tissue surrounding the main tumor would 
not likely receive a lethal dose. These images clearly reveal residual tumor shown later 
by PET to be metabolically active. Thus, the clinical findings parallel the PET derived 
treatment plan. In the other patients studied, the recurrences occurred locally in the 
edematous tissue region - tumor edge region. These findings are in agreement with 
the experience from the BNCT clinical trials at Brookhaven National Laboratory that 
showed the usual recurrence was local in nature rather than distant.l2 
The PET derived isodose contours correspond more closely to the observed 
BNCT clinical results than do the isodose contours generated by conventional 
calculations. This is important since these contours are used for treatment planning 
designed to eliminate the entire tumor, including the infiltrative portions, and not just the 
primary tumor mass. The lack of homogeneity in the tumor region, as well as in the 
surrounding tissues, leads to significant differences in dose calculations. Since the 
majority of the dose comes from the "B(n,~x)~Li reaction, the resulting isodose contours 
must be at least qualitatively similar to the actual 'OB distribution. The inhomogeneities 
seen in the PET images correspond much more closely to reality than the current 
assumption of homogeneous distributions. 
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Figure 3. Serial MRI images for a representative patient 
PET derived treatment plans indicate a significantly higher tumor dose that falls 
off much more rapidly than previously predicted. This rapid fall off in the BNCT 
radiation dose suggests that the dose to the edematous region is insufficient to kill the 
tumor cells in the edematous region around the tumor. This leads to inadequate 
treatment for an infiltrative tumor such as a GBM and has important implications for 
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other tumors that might be amenable to BNCT. This inadequate radiation dose could 
be due to an inadequate BPA concentration or to the lack of near neighbor effects 
which would increase the total radiation dose to a given cell. BNCT performed with 
BPA would appear to be best suited for tumors such as metastatic malignant 
melanoma, which grow by direct extension rather than infiltration. 
B. 
We were able to carry out a serial PET investigation on a Post-BNCT patient 
using both 18F-BPA and a carbon-I 1 labeled aminocyclobutanecarboxylic and, ' 'C- 
ACBC. This agent is one member of a family of positron labeled, unnatural, cyclic 
amino acids that have been under development at The University of Tennessee 
New Boronated Agents for Potential Use in BNCT 
Medical Center for use in imaging tumors. In a series of experimental clinical 
investigations, we have found that the four membered ring, ACBC, has proven to be 
quite effective for imaging brain tumors. 
"C -ACBC 
We were able to compare 'IC-ACBC in a post BNCT patient who had also been 
imaged with 18F-BPA a few days earlier. The results were striking in that the PET 
scans revealed that "C-ACBC was as tumor selective as I8F-BPA as can be seen in 
Figure 4. The selectivity of 'IC-ACBC led us to prepare a series of boronated ACBC 
analogues. 
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Figure 4. PET scans of Post-BNCT Patient Using I8F-BPA- 
Fructose (left) and 'IC-ACBC (right). 
The effectiveness of carbon-I 1 labeled aminocyclobutanecarboxylic acid 
(ACBC) in localizing in GBM tumors led us to investigate its potential use in BNCT. We 
targeted a series of boronated ACBC derivatives with side chains that contained either 
single or multiple boron atoms. We initiated the study with the syntheses of carborane 
substituted ACBC derivatives. There are three isomers of carborane (ortho, mefa, and 
para) each containing ten boron atoms. They differ only in the location of the two 
carbon atoms. 
ortho meta para 
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We first synthesized a carboranyl substituted 1 -aminocyclobutanecarboxylic 
acid, 2 
n 
2 
The compound was evaluated in vitro with respect to toxicity and cellular uptake. 
The toxicity studies were carried out in A549 human cancer cell cultures and revealed 
that cell growth was not suppressed at boron levels up to 10 micrograms of boron per 
ml of suspension over a period of 24 hours. The boron uptake in the cells was 
determined by inductively coupled plasma mass spectroscopy and were found to be on 
the order of 250 ng of boron per cell which far exceeds the cellular boron concentration 
obtained in similar experiments utilizing BPA (on the order of 10 ng of boron per cell), 
which compares favorably with values reported for porphyrin derivatives. 
Preliminary biodistribution studies using mice carrying transplanted gliomas 
were hampered by the high lipophilicity of the carboranyl ACBC. To enhance solubility 
we synthesized a nido-mefa-carboranyl ACBC. The compound was injected into nuhu 
mice which had been implanted with a human glioblastoma tumor. The preliminary 
biodistribution data were rather remarkable in that the tumor to normal brain tissue 
uptake was greater than twice that observed for BPA (Table 1) 
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Table 1 ; 
dodecacaboran( 1 2)-I -yl)ethyl]cyclobutanecarboxyli 
IN VlVO STUDY OF 1 -AMINO-3-[2-(7-(2-hydroxyethyl)-l ,7-dicarba-nido- 
Mice 
# 
1 
2 
3 
4 
Molecular formula: C11H26B903N Na 
Formula weight: 349.2 
% of Boron: 28.57 
Gender Weight Volume Boron Sacrifice Boron (ppm) in 
Nu/nu (9) injectd (ppm) time (h) Tumor Brain Blood Muscle 
(mL) whole 
body 
Male 16.7 1 102.65 3 51.7, 7.6 --- 37.4 
Male 19.4 1 88.36 6 7.1, 1.5 29.8 5.1 
Male 11.6 0.5 39.86 12 36.8, 3.7 --- 20.1 
51.5 
8.8 
29.8 
1 .I 
Male 21.5 0.5 73.89 24 1.3, 0.5 1.3 0.7 
Concentration of drug injected: 6 mg/mL; 1.71 mg B/mL; 1714 ppm of B/mL 
Boron analyses of the tissue samples 
Unfortunately, the data were inconsistent which can be attributed to the ionic 
nature of the nido-carborane cage. It is known that ionic-carborane derivatives can 
react with proteins resulting in nonspecific binding to biological materials. To obviate 
the possibility that the nido-carborane was the source of the biological inconsistencies, 
we then synthesized hydroxy derivative (3) that we postulated would be less lipophilic 
than the initially prepared mefa-carboranyl ACBC derivative. Once again the biological 
studies were hampered by the poor water solubility of the mefa-carborane moiety. 
C 02H 
" 2  
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More recently, we prepared two polyol substituted carboranyl ACBC derivatives. 
The cascade polyol 4 appeared promising in that it was quite soluble (>60 g/liter). 
“2 
4 
Unfortunately, in vivo tests in mice revealed unexpected toxicity. We then 
prepared a carbohydrate derivative 5 containing a galactose fragment. 
BH 
HO 
OH 
OH 
5 
This compound demonstrated no toxicity in beast cancer cells. In this test, A435 
cancer cells were grown in Leibovitz’s (L-I 5) minimum essential medium containing 
various concentrations of the boronated amino acids. The 2000 cells were then plated 
allowed to grow for a week and the colonies were counted and compared to control 
colonies. Within experimental error, the number of colonies was identical for the 
control and for the boron-containing cells. The compound will be tested in mice 
containing human transplanted to tumors by our colleagues at Washington State 
University.. 
We synthesized a boronic acid derivative of ACBC. The first reagent proved to 
be quite promising in that the tumor-normal tissue selectivity remained excellent and 
the blood values decreased dramatically. 
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Table 2:  In Vivo Study of a Boronic Acid Derivative of ACBCMolecular Formula: 
C8H14BN05Formula Weight: 21 5 
% of Boron: 5.03% 
Concentration: 1.8 mg B/mL (H20) 
Injection: 0.3 mL 
Mice: 20 g nuhu 
Mouse ## 
A I  
A2 
A3 
A4 
A5 
A6 
We also prepared a series of para-boronophenyl derivatives of ACBC, 6-9. The 
6,n=0 
7 , n = 2  
8 , n = 3  
9 , n = 7  
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materials were shown to be non toxic to the A435 cells in the in vitro tests. 
Unfortunately, the molecules exhibited poor solubility and tests in mice bearing human 
melanoma tumors were inconclusive. Fructose complexes of these reagents will be 
prepared and sent to Washington State University for further in vivo testing. 
More recently, a series of related cyclic am ino acids have been prepared. 
These agents have also demonstrated little toxicity in in vitro cell cultures. Their 
I 
OH 
10 (n  = 1) 
11 (n = 3 )  
fructose complexes will be prepared and sent for in vivo analyses in mice bearing 
human melanoma tumors. The tests will be carried out in collaboration with our 
colleagues at Washington State University and INEEL. 
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